The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
that's just a interview segment
Short term its 130. then 155ish. then usually double the breakout so 240/250
But thats purely on a technical basis, with news like this I think those levels dont really matter...
Looking forward to next week , glad I didn’t top
Slice or sell half to be safe !
On days like these don’t you wish you had a 40% holding in Tils.....
wonder where the next resistance would be in the short term if this bull run continues in the short term. $10? Chartists on the group, any predictions?
greater exposure would mean greater awareness amongst PIs about their products which would translate to bigger price when they spin off stem or any other of our other products..15k/month is peanuts if we look at the bigger picture
I have followed Redchip for a while and a couple of other companies I invested in used them, which seemed purely coincidence. Redchip tends to cover early stage lesser known companies. I tend to take their prompting somewhat skeptically akin to house broker notes i.e. they are paid to cover the company.
I suspect it'll be a short term arrangement with Redchip as once they have done the initial promoting the word gets out and tends to be diminishing returns on future videos.
Not concerned they are using them and $45K for promotion isn't huge given the opportunities.
Mr Smith thing to remember is pharma is the only industry which can jump into the billions overnight on news. One drug all it takes. And to derisk tils we have had 2 bodies independently verify the effectiveness of StemprintER technology. This is a win win, just need to hold for a long time to extract max value unless big pharma pounces
My only issue with tils is it does seem too good to be true! Does make me a little nervous but still..
Brilliant interview. This kunwar chap knows how to market the company that's for sure and is very sharp. The CEO is saying this company will be worth billions if one of those 3 drugs hit. And he sounds pretty confident. Goldmine this
I thought this what their broker Is suppose to do, approach companies to get exposure and investments ?
Do anyone else think this seems a bit fishy, or is it because I cant believe my ears.. ??
Tiziana Life Sciences (TLSA) is a client of RedChip Companies, Inc. TLSA agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2020, increasing to $15,000 monthly in August 2020, and $20,000 monthly in October 2020, for RedChip investor awareness services.
Im shocked they have to pay that amount of money to get exposure ???
Is this so they can execute the ATM at a higher price - Are they trying to get people to ramp the SP ?
Never known of a company paying to give interviews before ..
Is this common ?
previous to this interview we knew of 'several nda's' we now know it is 5 and those 5 have dictated how they want the phase 2 studies to progress. The crohns study is especially interesting in that the oral method is what big pharma wants to see and a third party study has shown it works in humans so kunwar sees it as derisked. Open door to a billion dollar market. ps we have several of these and i would imagine each big pharma is eyeing particular drugs/technology/condition combinations. Furthermore if nasal, oral or inhalation works then TILS is worth billions straightaway as it is a 'transformational technology'. I feel the interviewer was a bit shocked when kunwar said that stemprinter is 40% better than the market leader having been tested on 3200 patients and repeated for the viewers that oncotype DX sold for $2.8bn.
That website is a RedChip website it looks like Tiziana are just doing some advertising/PR through them. Disclosure at the bottom states:
Tiziana Life Sciences (TLSA) is a client of RedChip Companies, Inc. TLSA agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2020, increasing to $15,000 monthly in August 2020, and $20,000 monthly in October 2020, for RedChip investor awareness services.
wow! its an embarrassment of riches!
"if any of the 3 delivery systems work the company will be worth billions" thats even ignoring stemprinter etc!
is this website new not seen it before: http://tlsainfo.com/
i might sell the house and invest it!